Compugen to Present Cancer Immunotherapy Programs at Three International Cancer Conferences in March
February 20 2014 - 7:00AM
Business Wire
Compugen Ltd. (NASDAQ: CGEN) today announced that its scientists
are presenting at three international cancer conferences next
month:
Cancer Progress, March 4-5, 2014 in New York,
NY
Galit Rotman, PhD, Chief Scientist of Therapeutics, Compugen:
Taking Immunotherapy Seriously: New Targets and Combinations
Immune Evolution in Cancer, March 9-13 in Whistler,
British Columbia, Canada
Ofer Levy, PhD, Principal Scientist, Compugen:
Identification of Novel Immune Checkpoints as Potential Targets for
Cancer Immunotherapy
1st Immunotherapy of Cancer Conference, March 12-14 in
Munich, Germany
Gady Cojocaru, PhD, Principal Scientist, Compugen:
Identification of Novel Immune Checkpoints as Targets for Cancer
Immunotherapy
Anat Cohen-Dayag, PhD, President and CEO of Compugen, stated,
“As the scientific and medical communities’ belief that cancer
immunotherapy represents a paradigm shift in cancer treatment
becomes more widely validated, numerous international scientific
conferences have been scheduled to highlight the exciting advances
being made. With respect to Compugen, we are very pleased to see
the growing recognition of our cancer immunotherapy related
accomplishments and programs as demonstrated in part by our
participation in these conferences. In the first half of March,
Compugen scientists will be presenting at three separate meetings
relating to cancer immunotherapy: Cancer Progress, organized by
Defined Health in New York; Immune Evolution in Cancer, a Keystone
Symposia event in Whistler, Canada; and the Immunotherapy of Cancer
Conference being held in Munich, Germany.”
About Compugen
Compugen is a leading drug discovery company focused on
therapeutic proteins and monoclonal antibodies to address important
unmet needs in the fields of immunology and oncology. The Company
utilizes a broad and continuously growing integrated infrastructure
of proprietary scientific understandings and predictive platforms,
algorithms, machine learning systems and other computational
biology capabilities for the in silico (by computer) prediction and
selection of product candidates, which are then advanced in its
Pipeline Program. The Company's business model includes
collaborations covering the further development and
commercialization of product candidates at various stages from its
Pipeline Program and various forms of research and discovery
agreements, in both cases providing Compugen with potential
milestone payments and royalties on product sales or other forms of
revenue sharing. Compugen’s wholly-owned U.S. subsidiary located in
South San Francisco is developing oncology and immunology
monoclonal antibody therapeutic candidates against its drug
targets. For additional information, please visit Compugen's
corporate website at www.cgen.com.
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by the use of
terminology such as “will,” “may,” “expects,” “anticipates,”
“believes,” and “intends,” and describe opinions about future
events. These forward-looking statements involve known and unknown
risks and uncertainties that may cause the actual results,
performance or achievements of Compugen to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. Some of these risks
are: changes in relationships with collaborators; the inability to
reach mutually agreeable terms and conditions with respect to
potential new collaborations, the impact of competitive products
and technological changes; risks relating to the development of new
products; and the ability to implement technological improvements.
These and other factors are discussed in the "Risk Factors" section
of Compugen’s most recent Annual Report on Form 20-F as filed with
the Securities and Exchange Commission as well as other documents
that may be subsequently filed by Compugen from time to time with
the Securities and Exchange Commission. In addition, any
forward-looking statements represent Compugen’s views only as of
the date of this release and should not be relied upon as
representing its views as of any subsequent date. Compugen does not
assume any obligation to update any forward-looking statements
unless required by law.
Compugen Ltd.Tsipi HaitovskyGlobal Media
Liaison+972-52-598-9892tsipihai5@gmail.com
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024